Hospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (172)

2024

  1. A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non-Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy

    European Oncology and Haematology, Vol. 20, Núm. 1, pp. 5-8

  2. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  3. Characteristics and Survival Outcomes of Patients with Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting

    JCO Precision Oncology, Vol. 8, Núm. 1

  4. Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

    Scientific Reports, Vol. 14, Núm. 1

  5. Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

    Journal of Medical Economics, Vol. 27, Núm. 1, pp. 1379-1387

  6. Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent

    Cancer Immunology, Immunotherapy, Vol. 73, Núm. 10

  7. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

  8. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  9. Sesgo de género en la profesión médica en España

    XLIII Jornadas de Economía de la Salud. Políticas públicas para la salud: perspectivas desde la economía y la sanidad

  10. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

  11. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

  12. The sooner, the better: early clearance of plasma circulating tumor DNA in patients with advanced KRAS G12C mutant non-small cell lung cancer

    Translational Lung Cancer Research

  13. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer

    Lung Cancer, Vol. 188

2023

  1. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study

    Clinical and Translational Oncology, Vol. 25, Núm. 1, pp. 283-291

  2. A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

    Journal of Clinical Pharmacology, Vol. 63, Núm. 5, pp. 583-592

  3. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

    The oncologist, Vol. 28, Núm. 3, pp. 258-267

  4. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  5. Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 25, 5, (1252-1267), 10.1007/s12094-022-03046-9)

    Clinical and Translational Oncology

  6. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy

    Cancers, Vol. 15, Núm. 24

  7. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 1-7